77.86

0.30% -0.1816

Edwards Lifesciences Corp (EW)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt EW? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$78.04

Offen:

$78

24-Stunden-Volumen:

3.25M

Relative Volume:

0.73

Marktkapitalisierung:

$45.66B

Einnahmen:

$5.54B

Nettoeinkommen (Verlust:

$4.18B

KGV:

11.12

EPS:

Netto-Cashflow:

$623.10M

1W Leistung:

+3.06%

1M Leistung:

+8.78%

6M Leistung:

+11.89%

1J Leistung:

-13.33%

1-Tages-Spanne:

$77.60

$78.37

1-Wochen-Bereich:

$75.35

$78.37

52-Wochen-Spanne:

$58.93

$95.25

Edwards Lifesciences Corp Stock (EW) Company Profile

Firmenname

Edwards Lifesciences Corp

Sektor

Healthcare (1179)

Branche

Medical Devices (155)

Telefon

(949) 250-2500

Adresse

ONE EDWARDS WAY, IRVINE, CA

Mitarbeiter

15,800

Twitter

@edwardslifesci

Nächster Verdiensttermin

2025-02-11

Neueste SEC-Einreichungen

EW's Discussions on Twitter

Vergleichen Sie EW mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EW Edwards Lifesciences Corp	77.84	43.88B	5.54B	4.18B	623.10M	7.00
ABT Abbott Laboratories	135.00	229.64B	42.34B	13.50B	6.66B	7.71
BSX Boston Scientific Corp	106.23	152.19B	17.55B	2.03B	2.72B	1.37
SYK Stryker Corp	389.22	148.31B	23.22B	2.86B	3.58B	7.40
MDT Medtronic Plc	86.21	110.06B	33.20B	4.26B	5.47B	3.29

Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-24	Hochstufung	Piper Sandler	Neutral → Overweight
2025-01-30	Hochstufung	Stifel	Hold → Buy
2025-01-16	Herabstufung	Wolfe Research	Peer Perform → Underperform
2024-12-16	Hochstufung	BofA Securities	Neutral → Buy
2024-10-11	Fortgesetzt	Morgan Stanley	Equal-Weight
2024-09-18	Herabstufung	Jefferies	Buy → Hold
2024-07-31	Hochstufung	Daiwa Securities	Neutral → Outperform
2024-07-29	Hochstufung	Wolfe Research	Underperform → Peer Perform
2024-07-25	Herabstufung	BofA Securities	Buy → Neutral
2024-07-25	Herabstufung	JP Morgan	Overweight → Neutral
2024-07-25	Herabstufung	Robert W. Baird	Outperform → Neutral
2024-07-25	Herabstufung	TD Cowen	Buy → Hold
2024-07-25	Herabstufung	Truist	Buy → Hold
2024-05-30	Eingeleitet	Goldman	Buy
2024-05-22	Hochstufung	Citigroup	Neutral → Buy
2024-05-14	Hochstufung	Deutsche Bank	Hold → Buy
2024-03-07	Hochstufung	BofA Securities	Neutral → Buy
2024-02-02	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-01-04	Herabstufung	Evercore ISI	Outperform → In-line
2023-12-11	Herabstufung	Citigroup	Buy → Neutral
2023-11-28	Herabstufung	Wolfe Research	Peer Perform → Underperform
2023-09-26	Hochstufung	Oppenheimer	Perform → Outperform
2023-07-19	Eingeleitet	Robert W. Baird	Outperform
2023-05-30	Fortgesetzt	Morgan Stanley	Overweight
2023-03-29	Eingeleitet	UBS	Neutral
2023-03-08	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-02-06	Herabstufung	Raymond James	Outperform → Mkt Perform
2023-01-31	Herabstufung	Bernstein	Outperform → Underperform
2023-01-30	Herabstufung	Piper Sandler	Overweight → Neutral
2022-12-06	Herabstufung	Stifel	Buy → Hold
2022-10-28	Herabstufung	Oppenheimer	Outperform → Perform
2022-10-26	Eingeleitet	Mizuho	Buy
2022-10-18	Eingeleitet	Barclays	Overweight
2022-10-12	Eingeleitet	Jefferies	Buy
2022-07-29	Herabstufung	Canaccord Genuity	Buy → Hold
2022-04-13	Eingeleitet	Truist	Buy
2022-04-06	Eingeleitet	Wolfe Research	Outperform
2022-03-16	Hochstufung	Bernstein	Mkt Perform → Outperform
2022-03-02	Fortgesetzt	BofA Securities	Neutral
2022-02-02	Hochstufung	UBS	Neutral → Buy
2022-01-27	Bestätigt	Citigroup	Buy
2022-01-27	Bestätigt	Evercore ISI	Outperform
2022-01-27	Bestätigt	Raymond James	Outperform
2022-01-27	Bestätigt	Stifel	Buy
2022-01-27	Bestätigt	UBS	Neutral
2021-12-17	Hochstufung	JP Morgan	Neutral → Overweight
2021-12-15	Hochstufung	Citigroup	Neutral → Buy
2021-12-10	Eingeleitet	RBC Capital Mkts	Outperform
2021-12-06	Hochstufung	Wells Fargo	Equal Weight → Overweight
2021-07-30	Bestätigt	Canaccord Genuity	Buy
2021-07-30	Bestätigt	Deutsche Bank	Hold
2021-07-30	Bestätigt	Jefferies	Buy
2021-07-30	Bestätigt	Morgan Stanley	Overweight
2021-07-30	Bestätigt	Oppenheimer	Outperform
2021-07-30	Bestätigt	Stifel	Buy
2021-07-30	Bestätigt	UBS	Neutral
2021-07-30	Bestätigt	Wells Fargo	Equal Weight
2021-05-25	Eingeleitet	Barclays	Overweight
2021-04-15	Eingeleitet	Atlantic Equities	Neutral
2021-04-05	Hochstufung	Evercore ISI	In-line → Outperform
2020-12-16	Herabstufung	Citigroup	Buy → Neutral
2020-12-11	Bestätigt	Canaccord Genuity	Buy
2020-09-11	Eingeleitet	Wolfe Research	Underperform
2020-04-28	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-17	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2020-03-05	Eingeleitet	Citigroup	Buy
2020-02-13	Eingeleitet	Goldman	Neutral
2020-02-06	Fortgesetzt	BTIG Research	Neutral
2020-01-10	Eingeleitet	Oppenheimer	Outperform
2020-01-02	Herabstufung	Evercore ISI	Outperform → In-line
2019-10-24	Bestätigt	Canaccord Genuity	Buy
2019-09-23	Eingeleitet	Piper Jaffray	Overweight
2019-07-24	Bestätigt	BofA/Merrill	Buy
2019-03-18	Bestätigt	Canaccord Genuity	Buy
2019-01-18	Hochstufung	BofA/Merrill	Neutral → Buy
2019-01-03	Eingeleitet	Deutsche Bank	Hold
2018-11-28	Eingeleitet	UBS	Neutral
2018-10-16	Eingeleitet	Barclays	Underweight
2018-10-02	Herabstufung	BofA/Merrill	Buy → Neutral
2018-10-02	Herabstufung	Guggenheim	Buy → Neutral

Alle ansehen

Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten

May 16, 2025

Should Edwards Lifesciences Stock Remain in Your Portfolio Now? - Yahoo Finance

May 16, 2025

May 15, 2025

Movers & Shakers: Grant Thornton, United Drug, Edwards Lifesciences, Fine Grain, Viatel, Kepak, EU Commission - Business Post

May 15, 2025

May 14, 2025

Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges By Investing.com - Investing.com Canada

May 13, 2025

Edwards Lifesciences (EW) Sees Price Target Increase by Piper Sa - GuruFocus

May 13, 2025

Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges - Investing.com

May 13, 2025

Piper Sandler Adjusts Price Target on Edwards Lifesciences to $83 From $80, Maintains Overweight Rating - marketscreener.com

May 13, 2025

Piper Sandler raises Edwards Lifesciences target to $83 - Investing.com

May 13, 2025

May 12, 2025

FDA Clears New Indication for Edwards’ Sapien 3 - Orange County Business Journal

May 12, 2025

May 09, 2025

Why Edwards Lifesciences (EW) Is Among the Best Medical Device Stocks to Buy Now - Insider Monkey

May 09, 2025

May 08, 2025

Edwards Lifesciences Corporation (EW) Announces Amendments to Employee Stock Purchase Plans - GuruFocus

May 08, 2025

Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus

May 08, 2025

Edwards Lifesciences First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance

May 08, 2025

May 06, 2025

Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan

May 06, 2025

Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference - Yahoo Finance

May 06, 2025

May 02, 2025

Edwards Lifesciences (NYSE:EW) Receives FDA Approval For Groundbreaking TAVR Therapy For Asymptomatic Patients - Yahoo Finance

May 02, 2025

May 01, 2025

Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com

May 01, 2025

Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice

May 01, 2025

Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis - BioSpace

May 01, 2025

FDA approves Edwards Lifesciences’ TAVR therapy By Investing.com - Investing.com India

May 01, 2025

FDA approves Edwards Lifesciences’ TAVR therapy - Investing.com

May 01, 2025

Apr 30, 2025

Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite? - Insider Monkey

Apr 30, 2025

Apr 28, 2025

Commit To Purchase Edwards Lifesciences At $60, Earn 6.8% Using Options - Nasdaq

Apr 28, 2025

Apr 26, 2025

Edwards Lifesciences Corporation (NYSE:EW) Q1 2025 Earnings Call Transcript - Insider Monkey

Apr 26, 2025

Apr 25, 2025

Edwards Lifesciences Reports Robust Q1 2025 Growth - TipRanks

Apr 25, 2025

Edwards Lifesciences (EW) Price Target Raised by Canaccord Analy - GuruFocus

Apr 25, 2025

Apr 24, 2025

Edwards Lifesciences Raises 2025 Sales Forecast Amid Currency Boost - Finimize

Apr 24, 2025

Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook BrightensEdwards Lifesciences (NYSE:EW) - Benzinga

Apr 24, 2025

Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings - Yahoo Finance

Apr 24, 2025